Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.570
-0.050 (-3.09%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Galmed Pharmaceuticals Employees
As of December 31, 2024, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,252,833
Market Cap
3.55M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GLMD News
- 10 days ago - Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PRNewsWire
- 12 days ago - Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - PRNewsWire
- 17 days ago - Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PRNewsWire
- 25 days ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - PRNewsWire
- 5 weeks ago - Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PRNewsWire
- 7 months ago - Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PRNewsWire
- 7 months ago - Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 - PRNewsWire